IP Library Granted Patent US 7,705,036
Granted Patent B2
US 7,705,036 · App. 11/581,225 · Granted Apr 27, 2010

Deuterated aminocyclohexyl ether compounds and processes for preparing same

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,705,036
App. No.
11/581,225
Granted
Apr 27, 2010
Kind
B2
Abstract

This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.

Claims (172)

1. A compound of formula (I):

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

2. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

3. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

4. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

5. The compound of claim 1 wherein:

R 1 and R 2 are both deuterium;

R 3 and R 4 are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

6. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is —OCD 3 ;

R 10 is hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

7. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is hydroxy, methoxy or —OCD 3 ;

R 10 is —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

8. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

9. The compound of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I):

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

11. A compound of formula (II):

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 and R 13 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 and R 13 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

12. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

13. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

14. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

15. The compound of claim 11 wherein:

R 1 and R 2 are both deuterium;

R 3 and R 4 are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

16. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is —OCD 3 ;

R 10 is hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

17. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is hydroxy, methoxy or —OCD 3 ;

R 10 is —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

18. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is deuterium; and

R 12 and R 13 are both hydrogen or are both deuterium.

19. The compound of claim 11 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium; and

R 12 and R 13 are both deuterium.

20. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (II):

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 and R 13 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 and R 13 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2007
From: CHOU, DOUG TA HUNG; PLOUVIER, BERTRAND M. C.; PANG, PETER; YEE, JAMES GEE KEN; WHEELER, JEFFERY JEROME; YIFRU, AREGAHEGN S.; DAVIDOFF, ALLEN W.
To: CARDIOME PHARMA CORP.
Reel/Frame 018698/0890 →
Continuity (8)
Continuation In Part 1145528000 · Jun 15, 2006
Continuation In Part PCTUS200602366800 · Jun 15, 2006
Continuation In Part PCTUS200501112400 · Mar 31, 2005
Provisional Application 6069098900 · Jun 15, 2005
Provisional Application 6074824800 · Dec 7, 2005
Provisional Application 6058699200 · Jul 8, 2004
Provisional Application 6055940500 · Apr 1, 2004
Related Publication 20070088075A1 · Apr 19, 2007